human rrm2 reverse Search Results


94
Genecopoeia rrm2 promoter reporters
(A) dNTP production in small interfering RNA (siRNA)-transfected cells. dNTP was detected at both 48 hours and 72 hours post-transfection of siRNAs in C4-2 cells. siNS, nonspecific siRNA. (B) siRRM2-induced DNA damage. DNA damage marker activation was monitored in LNCaP and C4-2 cells using Muse multi-color DNA damage kit. (C) Activation of H2A.X was confirmed by immunoblotting. (D) and (E) Analysis of cell proliferation (D) and cell cycle (E) in transfected cells. (F) Apoptosis detected by Annexin V assays and immunoblots. (G) dNTP production in empty vector <t>(EV)/RRM2-overexpressing</t> PC-3 cells (PC3-EV; <t>PC3-RRM2).</t> (H) Cell proliferation in stable cells. (I) soft agar assays of stable PC-3 cells. The colony numbers were normalized to those in the control cells. (J) Wound healing assays after the scratch done for 24 hours. (K) Invasion assays after cells were plated for 48 hours. (L) and (M) EMT marker expression detected by qPCR (L) and immunoblots (M) in both EV- and RRM2-expressing PC-3 cells. (N) Invasion assays after multiple siRNAs were transfected in PC3-RRM2 cells. Figure 1 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 vs control groups treated with empty vector (EV) or with nonspecific (siNS) siRNA.
Rrm2 Promoter Reporters, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/Promoter+reporter+clone+for+Human+RRM2/pmc06820162-183-16-19
Average 94 stars, based on 1 article reviews
rrm2 promoter reporters - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
OriGene human rrm2 reverse
MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as <t>RRM2</t> ( G , H ) and RRM2B ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Human Rrm2 Reverse, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/RRM2+Human+qPCR+Primer+Pair/pmc08391410-89-8-14
Average 94 stars, based on 1 article reviews
human rrm2 reverse - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

88
Thermo Fisher gene exp rrm2 hs01072069 g1
Summary of correlative study results and relation to clinical outcomes
Gene Exp Rrm2 Hs01072069 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/Gene+Exp%2E+RRM2%2C+Hs01072069_g1/pmc03446256-171-20-15
Average 88 stars, based on 1 article reviews
gene exp rrm2 hs01072069 g1 - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology anti rrm2 antibody
Expression levels of <t>RRM2</t> subunit in gastric cancer cell lines. (A) Expression levels of the RRM2 subunit were examined by western blotting. Each group of samples was measured separately under the same exposure conditions. Almost all cell lines expressed RRM2; however, RRM2 expression was very low in MKN45 cells. (B) Expression levels of RRM2 were examined in MKN45 cells infected with T-hTERT. MKN45 cells were infected with PBS (−) (left), T-null (middle) or T-hTERT (right). (C) Expression levels of RRM2 in MKN45 cells were semi-quantified using a densitometer and RRM2 expression was increased almost 5-fold compared with the T-null group. *P<0.005. RRM2, <t>ribonucleotide</t> <t>reductase</t> <t>M2;</t> hTERT, human telomerase reverse transcriptase; T-hTERT, oncolytic HSVs which contain the ICP6 gene under the regulation of the hTERT promoter; T-null, oncolytic HSVs which contain the ICP6 gene not regulated by the hTERT promoter.
Anti Rrm2 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/%CE%B2-Actin+Antibody/pmc08100961-132-0-3
Average 96 stars, based on 1 article reviews
anti rrm2 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology human rrm2 gene specific sirna
Overexpression of <t>RRM2</t> decreased TSP-1 expression in KB-M2-D and KB-HURs cells . (A) Western blot analysis confirmed that only RRM2 was overexpressed in KB-M2-D and KB-HURs; the expression of RRM1 and p53R2 was not significantly modulated in both KB-M2-D and KB-HURs; and the expression of TSP-1 was significantly decreased in KB-M2-D and KB-HURs cells by 60%~70% (TSP1-CM: TSP-1 in concentrated condition medium, TSP1-T: TSP-1 in total protein). (B) Representative quantitative densitometric analysis of RRM2 and TSP-1 expression. Signal intensities were normalized to that of β-actin serving as loading control; data was presented as fold of KB. (C) q-RT-PCR analysis confirmed that RRM2 mRNA was dramatically overexpressed in KB-M2D and KB-HURs compared with parental KB (** p < 0.01). Values of q-RT-PCR were the mean ± SD of three independent experiments and presented as ratio to the level of parental KB cells. (D) q-RT-PCR analysis showed TSP-1 mRNA was significantly decreased in KB-M2D and KB-HURs compared with parental KB (** p < 0.01).
Human Rrm2 Gene Specific Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/R2+siRNA/pmc02662784-51-1-13
Average 93 stars, based on 1 article reviews
human rrm2 gene specific sirna - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc rrm2 antibody
Figure 1. In vitro gene silencing efficiency. (A) Relative luciferase activity and cell viability after transfection with EAAS/siRNA and EDAS/siRNA complexes at w/w ratio of 9 and siRNA concentration of 50 nM. (B) Relative <t>RRM2</t> mRNA level was detected by RT-PCR assay. RRM2 protein level was detected by western blot assay (C) and quantitatively analyzed by Image J software (D). Relative luciferase activity and cell viability were detected after transfected with EAASc/siRNA complexes (E) at different w/w ratios and (F) different siRNA concentrations. To confirm the gene silencing efficiency, relative RRM2 mRNA levels in (G1) HepG2 cells, (G2) MDA-MB-231 cells, (G3) 293A cells, and (G4) Hela cells were also detected at different w/w ratios (5.5, 9, and 14.5) and siRRM2 concentrations (20 nM, 50 nM, and 80 nM). Each bar represents Mean ± SEM of three experiments. * p<0.05, ** p<0.01, and *** p<0.001 vs Naked siRNA group.
Rrm2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/RRM2+XP+Rabbit+mAb/pm29870899-34-0-5
Average 94 stars, based on 1 article reviews
rrm2 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
OriGene human rrm2b
MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as RRM2 ( G , H ) and <t>RRM2B</t> ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Human Rrm2b, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/p53R2+(RRM2B)+Human+qPCR+Primer+Pair/pmc08391410-89-18-28
Average 90 stars, based on 1 article reviews
human rrm2b - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology scramble sirna
Knockdown <t>of</t> <t>RRM2</t> increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 <t>siRNA.</t> (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.
Scramble Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/SC+siRNA/pmc02662784-51-8-13
Average 95 stars, based on 1 article reviews
scramble sirna - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
Becton Dickinson software v10.7.2
Knockdown <t>of</t> <t>RRM2</t> increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 <t>siRNA.</t> (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.
Software V10.7.2, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/v10+7+1/pm36130505-318-221-222
Average 90 stars, based on 1 article reviews
software v10.7.2 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc anti pbrm baf180
Knockdown <t>of</t> <t>RRM2</t> increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 <t>siRNA.</t> (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.
Anti Pbrm Baf180, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/PBRM1%2FBAF180+Rabbit+mAb/pmc08727810-96-76-78
Average 93 stars, based on 1 article reviews
anti pbrm baf180 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

99
Bio-Rad cfx96 real time pcr detection system
Knockdown <t>of</t> <t>RRM2</t> increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 <t>siRNA.</t> (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.
Cfx96 Real Time Pcr Detection System, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/CFX96+and+CFX384+Real-Time+PCR+Detection+Systems+Firmware+Update/pmc05636969-194-26-31
Average 99 stars, based on 1 article reviews
cfx96 real time pcr detection system - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc egfr
AFAP1-AS1 <t>upregulates</t> <t>RRM2</t> expression by sponging miR-139-5p. (A) The potential binding sites between RRM2 and miR-139-5p predicted by bioinformatics. All binding sites in the RRM2 3′ UTR were mutated and named “RRM2 MUT”. (B,C) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (D) RT-PCR on the cDNA from A549 cells to determine the effect of miR-139-5p on RRM2 mRNA expression. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected A549 cells. (E,F) Western blot on the effect of miR-139-5p on protein expression of RRM2, <t>EGFR,</t> AKT, and p-AKT in A549 and SPCA-1 cells. (G) RT-PCR on the expression of RRM2 mRNA in NSCLC tissues ( n = 44) and in adjacent normal tissues ( n = 20). Data shown as means ± S.D. # P < 0.05 compared with the normal tissues. (H) The mRNA level of RRM2 in chemotherapy response ( n = 4) and resistance ( n = 7) NSCLC tumors by RT-PCR. The results shown as means ± S.D. # P < 0.05 compared with the response group. (I) RRM2 mRNA expression in lung cancer cells analyzed by RT- PCR. The results shown as means ± S.D. # P < 0.05 compared with BEAS-2B cells. (J,K) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (L,M) Western blot on the effect of miR-139-5p and AFAP1-AS1 on protein expression of RRM2in A549 and SPCA-1 cells.
Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+rrm2+reverse/EGF+Receptor+(E746-A750del+Specific)+XP+Rabbit+mAb/pmc06817562-113-22-39
Average 95 stars, based on 1 article reviews
egfr - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


(A) dNTP production in small interfering RNA (siRNA)-transfected cells. dNTP was detected at both 48 hours and 72 hours post-transfection of siRNAs in C4-2 cells. siNS, nonspecific siRNA. (B) siRRM2-induced DNA damage. DNA damage marker activation was monitored in LNCaP and C4-2 cells using Muse multi-color DNA damage kit. (C) Activation of H2A.X was confirmed by immunoblotting. (D) and (E) Analysis of cell proliferation (D) and cell cycle (E) in transfected cells. (F) Apoptosis detected by Annexin V assays and immunoblots. (G) dNTP production in empty vector (EV)/RRM2-overexpressing PC-3 cells (PC3-EV; PC3-RRM2). (H) Cell proliferation in stable cells. (I) soft agar assays of stable PC-3 cells. The colony numbers were normalized to those in the control cells. (J) Wound healing assays after the scratch done for 24 hours. (K) Invasion assays after cells were plated for 48 hours. (L) and (M) EMT marker expression detected by qPCR (L) and immunoblots (M) in both EV- and RRM2-expressing PC-3 cells. (N) Invasion assays after multiple siRNAs were transfected in PC3-RRM2 cells. Figure 1 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 vs control groups treated with empty vector (EV) or with nonspecific (siNS) siRNA.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A) dNTP production in small interfering RNA (siRNA)-transfected cells. dNTP was detected at both 48 hours and 72 hours post-transfection of siRNAs in C4-2 cells. siNS, nonspecific siRNA. (B) siRRM2-induced DNA damage. DNA damage marker activation was monitored in LNCaP and C4-2 cells using Muse multi-color DNA damage kit. (C) Activation of H2A.X was confirmed by immunoblotting. (D) and (E) Analysis of cell proliferation (D) and cell cycle (E) in transfected cells. (F) Apoptosis detected by Annexin V assays and immunoblots. (G) dNTP production in empty vector (EV)/RRM2-overexpressing PC-3 cells (PC3-EV; PC3-RRM2). (H) Cell proliferation in stable cells. (I) soft agar assays of stable PC-3 cells. The colony numbers were normalized to those in the control cells. (J) Wound healing assays after the scratch done for 24 hours. (K) Invasion assays after cells were plated for 48 hours. (L) and (M) EMT marker expression detected by qPCR (L) and immunoblots (M) in both EV- and RRM2-expressing PC-3 cells. (N) Invasion assays after multiple siRNAs were transfected in PC3-RRM2 cells. Figure 1 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 vs control groups treated with empty vector (EV) or with nonspecific (siNS) siRNA.

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: Small Interfering RNA, Transfection, Marker, Activation Assay, Western Blot, Plasmid Preparation, Control, Expressing

(A)-(C) The correlation of gene alteration with the fraction of genome altered (FGA) and Gleason grades in TCGA cohort was visualized in (A). The statistical quantitation was shown in (B) and (C). (D) The correlation of RRM2 level with Gleason grade in tumor and matched normal tissues in the PHS/HPFS cohorts. (E) and (F) The correlation of RRM2 expression with tumor progression in Taylor and Grasso cohorts. RRM2 levels were analyzed in prostate gland (PG), primary (Pri), and metastasis (Met) tissue samples. (G) The association of RRM2 expression and the disease-free survival in the TCGA, Taylor, and Glinsky cohorts. (H) The correlation of RRM2 with the risk of lethal prostate cancer over long-term follow-up, independent from clinical characteristics and Gleason grade, in the combined HPFS and PHS prostate cancer cohorts. The odd ratios for lethal disease were adjusted for Gleason score. ****, p<0.0001 vs comparator groups.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A)-(C) The correlation of gene alteration with the fraction of genome altered (FGA) and Gleason grades in TCGA cohort was visualized in (A). The statistical quantitation was shown in (B) and (C). (D) The correlation of RRM2 level with Gleason grade in tumor and matched normal tissues in the PHS/HPFS cohorts. (E) and (F) The correlation of RRM2 expression with tumor progression in Taylor and Grasso cohorts. RRM2 levels were analyzed in prostate gland (PG), primary (Pri), and metastasis (Met) tissue samples. (G) The association of RRM2 expression and the disease-free survival in the TCGA, Taylor, and Glinsky cohorts. (H) The correlation of RRM2 with the risk of lethal prostate cancer over long-term follow-up, independent from clinical characteristics and Gleason grade, in the combined HPFS and PHS prostate cancer cohorts. The odd ratios for lethal disease were adjusted for Gleason score. ****, p<0.0001 vs comparator groups.

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: Quantitation Assay, Expressing

(A) Gene set enrichment analysis (GSEA) of transcriptomic changes. The histograms showed the distribution of select top GSEA molecular signatures: MYC targets (MYC_up_V1_up gene set); E2F targets (hallmark_E2F_targets gene set), cell cycle (Module_54 gene set), p53 pathway (hallmark_p53_pathway), and apoptosis (hallmark apoptosis). Up-gene (up-regulated genes); Down-gene (down-regulated genes). (B) Multiple targets of pathways were validated by quantitative reverse transcription PCR (qRT-PCR). (C) siRRM2-regulated gene profiling and the correlation of these genes with disease-free survival (DFS) in Taylor cohort. (D) Significant enrichment in EMT and Angiogenesis gene sets in RRM2-overexpressing PC-3 cells. (E) RRM2-regulated 126-gene profiling and correlation with the clinical outcome in clinical cohorts. 126 genes were revealed by overlapping 1230 up-regulated genes in PC3-RRM2 cells with 627 common genes positively correlated with RRM2 overexpression in three prostate cancer cohorts (TCGA, Kumar, and SU2C/PCF). The correlation of these genes with disease-free survival was analyzed in the Taylor cohort.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A) Gene set enrichment analysis (GSEA) of transcriptomic changes. The histograms showed the distribution of select top GSEA molecular signatures: MYC targets (MYC_up_V1_up gene set); E2F targets (hallmark_E2F_targets gene set), cell cycle (Module_54 gene set), p53 pathway (hallmark_p53_pathway), and apoptosis (hallmark apoptosis). Up-gene (up-regulated genes); Down-gene (down-regulated genes). (B) Multiple targets of pathways were validated by quantitative reverse transcription PCR (qRT-PCR). (C) siRRM2-regulated gene profiling and the correlation of these genes with disease-free survival (DFS) in Taylor cohort. (D) Significant enrichment in EMT and Angiogenesis gene sets in RRM2-overexpressing PC-3 cells. (E) RRM2-regulated 126-gene profiling and correlation with the clinical outcome in clinical cohorts. 126 genes were revealed by overlapping 1230 up-regulated genes in PC3-RRM2 cells with 627 common genes positively correlated with RRM2 overexpression in three prostate cancer cohorts (TCGA, Kumar, and SU2C/PCF). The correlation of these genes with disease-free survival was analyzed in the Taylor cohort.

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: Reverse Transcription, Quantitative RT-PCR, Over Expression

(A) dNTP production in COH29-treated C4-2 cells. Two doses of COH29 were used in C4-2 cells, and dNTP production was detected after 24 hours of treatment. (B) and (C) Activation of DNA damage markers. (D) Cell proliferation assay. (E) Cell cycle analysis after 48 hours of COH29 treatment. (F) COH29-induced apoptosis. (G) The global mRNA changes induced by COH29 in C4-2 cells, after 48 hours of treatment. (H) GSEA analysis of mRNA profiling in 20 μM of COH29-treated cells. The histograms showed the distribution of select top GSEA molecular signatures. Up-gene (COH29-induced up-regulated genes); Down-gene (COH29-induced down-regulated genes). NES, normalized enrichment score; FDR, false discovery rate. (I) and (J) Identification of targeted genes by inhibition of RRM2. Genes affected by inhibition of RRM2 in cells were overlapped with genes correlated with RRM2 overexpression in Taylor cohort to reveal 33 down-regulated genes and 12 up-regulated genes (I). These gene panels were validated in three additional prostate cancer cohorts (J). The Figure 4 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001 vs control groups.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A) dNTP production in COH29-treated C4-2 cells. Two doses of COH29 were used in C4-2 cells, and dNTP production was detected after 24 hours of treatment. (B) and (C) Activation of DNA damage markers. (D) Cell proliferation assay. (E) Cell cycle analysis after 48 hours of COH29 treatment. (F) COH29-induced apoptosis. (G) The global mRNA changes induced by COH29 in C4-2 cells, after 48 hours of treatment. (H) GSEA analysis of mRNA profiling in 20 μM of COH29-treated cells. The histograms showed the distribution of select top GSEA molecular signatures. Up-gene (COH29-induced up-regulated genes); Down-gene (COH29-induced down-regulated genes). NES, normalized enrichment score; FDR, false discovery rate. (I) and (J) Identification of targeted genes by inhibition of RRM2. Genes affected by inhibition of RRM2 in cells were overlapped with genes correlated with RRM2 overexpression in Taylor cohort to reveal 33 down-regulated genes and 12 up-regulated genes (I). These gene panels were validated in three additional prostate cancer cohorts (J). The Figure 4 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001 vs control groups.

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: Activation Assay, Proliferation Assay, Cell Cycle Assay, Inhibition, Over Expression, Control

(A)-(B) Phospho-kinase array analysis after 24-hour COH29 treatment in C4-2 cells. The whole-cell lysates were collected for human phospho-kinase array analysis. Each membrane contains kinase-specific antibodies (number indicated). Relative phosphorylation of spots was quantified by Image J software and the value of vehicle (0 μM) was set up as “1” (B). (C) Validation of phospho-kinase array by immunoblots. For siRNA-treated groups, cell lysates were collected after transfection for 48 hours. The representative blots for each condition are shown and the values represent the mean ± S.E. of two independent experiments. (D) Druggable RRM2 signatures. Top three drugs from ToppGene analysis and COH29 are shown (left panel). Numbers of genes down-regulated by docetaxel (in PC-3 cells) and docetaxel + ADT (in patients) are shown (right panel). (E)-(F) Antitumor effects of COH29 in vivo. Tumor volumes and weights were measured following oral administration of COH29 (200 mg/kg) in established C4-2 xenograft tumors (n=6 per group). Values are means ± S.E. ***P<0.001 versus vehicle mice. (G)-(H) Regulation of key genes by COH29 in vivo. Multiple genes regulated by COH29 were assessed in xenograft tumors by immunohistochemistry staining (G) or immunoblotting (H).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A)-(B) Phospho-kinase array analysis after 24-hour COH29 treatment in C4-2 cells. The whole-cell lysates were collected for human phospho-kinase array analysis. Each membrane contains kinase-specific antibodies (number indicated). Relative phosphorylation of spots was quantified by Image J software and the value of vehicle (0 μM) was set up as “1” (B). (C) Validation of phospho-kinase array by immunoblots. For siRNA-treated groups, cell lysates were collected after transfection for 48 hours. The representative blots for each condition are shown and the values represent the mean ± S.E. of two independent experiments. (D) Druggable RRM2 signatures. Top three drugs from ToppGene analysis and COH29 are shown (left panel). Numbers of genes down-regulated by docetaxel (in PC-3 cells) and docetaxel + ADT (in patients) are shown (right panel). (E)-(F) Antitumor effects of COH29 in vivo. Tumor volumes and weights were measured following oral administration of COH29 (200 mg/kg) in established C4-2 xenograft tumors (n=6 per group). Values are means ± S.E. ***P<0.001 versus vehicle mice. (G)-(H) Regulation of key genes by COH29 in vivo. Multiple genes regulated by COH29 were assessed in xenograft tumors by immunohistochemistry staining (G) or immunoblotting (H).

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: Membrane, Phospho-proteomics, Software, Biomarker Discovery, Western Blot, Transfection, In Vivo, Immunohistochemistry, Staining

(A) H3K27Ac ChIP-Seq in tissues. The binding signal on RRM2 enhancer (1Mb region) was quantified. (B) The strategy to identify RRM2-targeting transcription factors (TFs). Human TFs were selected in the genes positively correlated with RRM2 expression in prostate cancer cohorts. Yellow/orange/pink bars indicate that TFs appear in four/three/two cohorts. (C) The correlation of FOXM1 and RRM2 in PHS/HPFS cohorts. (D) FOXM1 binding on RRM2 promoter in cancer cells. The overview of multiple ChIP-Seq datasets were extracted from Cistrome Data browser. P1-P3 primers were designed for FOXM1 ChIP-PCR. (E) FOXM1 or H3K4me3-ChIP-PCR on RRM2 promoter. (F) RRM2 promoter activity regulated by FOXM1. The reporters without (R2-0K) or with (R2-3K) 3kb RRM2 promoter sequence were transfected in siRNA-treated 22Rv1 cells. (G) and (H) Inhibition of RRM2 expression by siFOXM1 in 22Rv1 and C4-2 cells. (I) Inhibition of FOXM1 targets by FDI-6 (20 μM) in 22Rv1 cells. The Figure 6 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001 vs control groups.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)

doi: 10.1158/1078-0432.CCR-18-4046

Figure Lengend Snippet: (A) H3K27Ac ChIP-Seq in tissues. The binding signal on RRM2 enhancer (1Mb region) was quantified. (B) The strategy to identify RRM2-targeting transcription factors (TFs). Human TFs were selected in the genes positively correlated with RRM2 expression in prostate cancer cohorts. Yellow/orange/pink bars indicate that TFs appear in four/three/two cohorts. (C) The correlation of FOXM1 and RRM2 in PHS/HPFS cohorts. (D) FOXM1 binding on RRM2 promoter in cancer cells. The overview of multiple ChIP-Seq datasets were extracted from Cistrome Data browser. P1-P3 primers were designed for FOXM1 ChIP-PCR. (E) FOXM1 or H3K4me3-ChIP-PCR on RRM2 promoter. (F) RRM2 promoter activity regulated by FOXM1. The reporters without (R2-0K) or with (R2-3K) 3kb RRM2 promoter sequence were transfected in siRNA-treated 22Rv1 cells. (G) and (H) Inhibition of RRM2 expression by siFOXM1 in 22Rv1 and C4-2 cells. (I) Inhibition of FOXM1 targets by FDI-6 (20 μM) in 22Rv1 cells. The Figure 6 values represent the mean ± S.E. of three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.001 vs control groups.

Article Snippet: For luciferase reporter assays, siRNAs were transfected in cells for 24 hours and 500 ng of RRM2 promoter reporters (GeneCopoeia) containing 0kb or 3kb promoter sequence of human RRM2 were cotransfected with Lipofectamine 2000 (Invitrogen).

Techniques: ChIP-sequencing, Binding Assay, Expressing, Activity Assay, Sequencing, Transfection, Inhibition, Control

MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as RRM2 ( G , H ) and RRM2B ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Journal: Cancers

Article Title: Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

doi: 10.3390/cancers13164200

Figure Lengend Snippet: MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as RRM2 ( G , H ) and RRM2B ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Article Snippet: The primers used were human RRM2 forward: CTGGCTCAAGAAACGAGGACTG; human RRM2 reverse: CTCTCCTCCGATGGTTTGTGTAC (#HP203086 premixed, Origene, Rockville, MD, USA); human RRM2b forward: ACTTCATCTCTCACATCTTAGCCT; human RRM2b reverse: AAACAGCGAGCCTCTGGAACCT (#HP211794 premixed, Origene); human RRM1 premixed, purchased from Realtimeprimers (#VHPS-8020, Elkins Park, PA, USA).

Techniques: MTT Viability Assay, Incubation, Real-time Polymerase Chain Reaction, Immunofluorescence, Western Blot, Expressing

Relative RRM1 and RRM2 gene expression in normal adrenal (NA), adrenocortical adenoma (ACA), and adrenocortical carcinoma (ACC) samples of an available series form the literature ( A , B ) and of our cohort ( C , D ). Kaplan–Meier survival curves for patients with ACC from our cohort according to low or high expression levels of RRM1 ( E ) or RRM2 ( F ). Correlation between the tumor size and the RRM2 expression levels ( G ).

Journal: Cancers

Article Title: Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

doi: 10.3390/cancers13164200

Figure Lengend Snippet: Relative RRM1 and RRM2 gene expression in normal adrenal (NA), adrenocortical adenoma (ACA), and adrenocortical carcinoma (ACC) samples of an available series form the literature ( A , B ) and of our cohort ( C , D ). Kaplan–Meier survival curves for patients with ACC from our cohort according to low or high expression levels of RRM1 ( E ) or RRM2 ( F ). Correlation between the tumor size and the RRM2 expression levels ( G ).

Article Snippet: The primers used were human RRM2 forward: CTGGCTCAAGAAACGAGGACTG; human RRM2 reverse: CTCTCCTCCGATGGTTTGTGTAC (#HP203086 premixed, Origene, Rockville, MD, USA); human RRM2b forward: ACTTCATCTCTCACATCTTAGCCT; human RRM2b reverse: AAACAGCGAGCCTCTGGAACCT (#HP211794 premixed, Origene); human RRM1 premixed, purchased from Realtimeprimers (#VHPS-8020, Elkins Park, PA, USA).

Techniques: Gene Expression, Expressing

Real-time PCR analysis of RRM2 ( A , D ) gene expression and number of surviving cells ( B , E ) under RRM2 siRNA knockdown for NCI-H295R and MUC-1, respectively. RRM2 gene expression upon etoposide and doxorubicin treatment for NCI-H295R and MUC-1 ( C , F ). Quantification of Western blots for p-Chk1 ( G ), p-Chk2 ( H ), and p-H2AX ( I ) for no treatment, gemcitabine, cisplatin, and combination of both (gemcitabine and cisplatin) 24 h after treatment. Schematic illustration of the related DNA damage–repair pathway, including relevant therapeutic inhibitors ( J ). Stars represent significance vs. nontreated (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001); ns, non-significant.

Journal: Cancers

Article Title: Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

doi: 10.3390/cancers13164200

Figure Lengend Snippet: Real-time PCR analysis of RRM2 ( A , D ) gene expression and number of surviving cells ( B , E ) under RRM2 siRNA knockdown for NCI-H295R and MUC-1, respectively. RRM2 gene expression upon etoposide and doxorubicin treatment for NCI-H295R and MUC-1 ( C , F ). Quantification of Western blots for p-Chk1 ( G ), p-Chk2 ( H ), and p-H2AX ( I ) for no treatment, gemcitabine, cisplatin, and combination of both (gemcitabine and cisplatin) 24 h after treatment. Schematic illustration of the related DNA damage–repair pathway, including relevant therapeutic inhibitors ( J ). Stars represent significance vs. nontreated (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001); ns, non-significant.

Article Snippet: The primers used were human RRM2 forward: CTGGCTCAAGAAACGAGGACTG; human RRM2 reverse: CTCTCCTCCGATGGTTTGTGTAC (#HP203086 premixed, Origene, Rockville, MD, USA); human RRM2b forward: ACTTCATCTCTCACATCTTAGCCT; human RRM2b reverse: AAACAGCGAGCCTCTGGAACCT (#HP211794 premixed, Origene); human RRM1 premixed, purchased from Realtimeprimers (#VHPS-8020, Elkins Park, PA, USA).

Techniques: Real-time Polymerase Chain Reaction, Gene Expression, Knockdown, Western Blot

Summary of correlative study results and relation to clinical outcomes

Journal: Cancer chemotherapy and pharmacology

Article Title: Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

doi: 10.1007/s00280-010-1481-z

Figure Lengend Snippet: Summary of correlative study results and relation to clinical outcomes

Article Snippet: The qPCR reactions were carried out in triplicate using cDNA and the following assays from Applied Biosciences (Foster City, CA): Hs01072069_g1 (ribonucleotide reductase M1 [RRM1]), Hs01040698_m1 (ribonucleotide reductase M2 [RRM2]), and Hs00968432_m1 (ribonucleotide reductase M2B [p53R2]).

Techniques: In Situ

a–d In situ RT–PCR analysis of RRM2 expression in fine needle tumor aspirate of tumor samples pre-treatment (a, c) and 24-h post-treatment (b, d) with gemcitabine and 3-AP in patients 4 (a, b) and 6 (c, d). Black arrows indicate nuclear staining, while gray arrows indicate cytoplasmic staining. There was qualitatively increased RRM2 mRNA expression when compared with pre-treatment samples in both patients, suggesting in vivo inhibition of ribonucleotide reductase

Journal: Cancer chemotherapy and pharmacology

Article Title: Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

doi: 10.1007/s00280-010-1481-z

Figure Lengend Snippet: a–d In situ RT–PCR analysis of RRM2 expression in fine needle tumor aspirate of tumor samples pre-treatment (a, c) and 24-h post-treatment (b, d) with gemcitabine and 3-AP in patients 4 (a, b) and 6 (c, d). Black arrows indicate nuclear staining, while gray arrows indicate cytoplasmic staining. There was qualitatively increased RRM2 mRNA expression when compared with pre-treatment samples in both patients, suggesting in vivo inhibition of ribonucleotide reductase

Article Snippet: The qPCR reactions were carried out in triplicate using cDNA and the following assays from Applied Biosciences (Foster City, CA): Hs01072069_g1 (ribonucleotide reductase M1 [RRM1]), Hs01040698_m1 (ribonucleotide reductase M2 [RRM2]), and Hs00968432_m1 (ribonucleotide reductase M2B [p53R2]).

Techniques: In Situ, Reverse Transcription Polymerase Chain Reaction, Expressing, Staining, In Vivo, Inhibition

QRT-PCR analysis of RRM1, RRM2, and RRM2b represents fold change in RRM1, RRM2, and RRM2b mRNA expression in peripheral blood mononuclear cells 24-h post-treatment with 3-AP plus gemcitabine in patients 4, 16, 27 and 31. Fold change is relative to pre-treatment sample, and all samples were normalized to TATA-binding protein (TBP). There was a quantitative decrease in PBMC RRM2 mRNA expression after 3-AP/gemcitabine therapy in 3 of 4 patients evaluated, and variable effects observed in RRM1 and RRM2b

Journal: Cancer chemotherapy and pharmacology

Article Title: Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

doi: 10.1007/s00280-010-1481-z

Figure Lengend Snippet: QRT-PCR analysis of RRM1, RRM2, and RRM2b represents fold change in RRM1, RRM2, and RRM2b mRNA expression in peripheral blood mononuclear cells 24-h post-treatment with 3-AP plus gemcitabine in patients 4, 16, 27 and 31. Fold change is relative to pre-treatment sample, and all samples were normalized to TATA-binding protein (TBP). There was a quantitative decrease in PBMC RRM2 mRNA expression after 3-AP/gemcitabine therapy in 3 of 4 patients evaluated, and variable effects observed in RRM1 and RRM2b

Article Snippet: The qPCR reactions were carried out in triplicate using cDNA and the following assays from Applied Biosciences (Foster City, CA): Hs01072069_g1 (ribonucleotide reductase M1 [RRM1]), Hs01040698_m1 (ribonucleotide reductase M2 [RRM2]), and Hs00968432_m1 (ribonucleotide reductase M2B [p53R2]).

Techniques: Quantitative RT-PCR, Expressing, Binding Assay

Expression levels of RRM2 subunit in gastric cancer cell lines. (A) Expression levels of the RRM2 subunit were examined by western blotting. Each group of samples was measured separately under the same exposure conditions. Almost all cell lines expressed RRM2; however, RRM2 expression was very low in MKN45 cells. (B) Expression levels of RRM2 were examined in MKN45 cells infected with T-hTERT. MKN45 cells were infected with PBS (−) (left), T-null (middle) or T-hTERT (right). (C) Expression levels of RRM2 in MKN45 cells were semi-quantified using a densitometer and RRM2 expression was increased almost 5-fold compared with the T-null group. *P<0.005. RRM2, ribonucleotide reductase M2; hTERT, human telomerase reverse transcriptase; T-hTERT, oncolytic HSVs which contain the ICP6 gene under the regulation of the hTERT promoter; T-null, oncolytic HSVs which contain the ICP6 gene not regulated by the hTERT promoter.

Journal: Oncology Letters

Article Title: Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer

doi: 10.3892/ol.2021.12751

Figure Lengend Snippet: Expression levels of RRM2 subunit in gastric cancer cell lines. (A) Expression levels of the RRM2 subunit were examined by western blotting. Each group of samples was measured separately under the same exposure conditions. Almost all cell lines expressed RRM2; however, RRM2 expression was very low in MKN45 cells. (B) Expression levels of RRM2 were examined in MKN45 cells infected with T-hTERT. MKN45 cells were infected with PBS (−) (left), T-null (middle) or T-hTERT (right). (C) Expression levels of RRM2 in MKN45 cells were semi-quantified using a densitometer and RRM2 expression was increased almost 5-fold compared with the T-null group. *P<0.005. RRM2, ribonucleotide reductase M2; hTERT, human telomerase reverse transcriptase; T-hTERT, oncolytic HSVs which contain the ICP6 gene under the regulation of the hTERT promoter; T-null, oncolytic HSVs which contain the ICP6 gene not regulated by the hTERT promoter.

Article Snippet: Anti-RRM2 antibody (sc-10846; Santa Cruz Biotechnology, Inc.) or goat polyclonal anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology, Inc.) were used as primary antibodies ( ).

Techniques: Expressing, Western Blot, Infection, Reverse Transcription

Overexpression of RRM2 decreased TSP-1 expression in KB-M2-D and KB-HURs cells . (A) Western blot analysis confirmed that only RRM2 was overexpressed in KB-M2-D and KB-HURs; the expression of RRM1 and p53R2 was not significantly modulated in both KB-M2-D and KB-HURs; and the expression of TSP-1 was significantly decreased in KB-M2-D and KB-HURs cells by 60%~70% (TSP1-CM: TSP-1 in concentrated condition medium, TSP1-T: TSP-1 in total protein). (B) Representative quantitative densitometric analysis of RRM2 and TSP-1 expression. Signal intensities were normalized to that of β-actin serving as loading control; data was presented as fold of KB. (C) q-RT-PCR analysis confirmed that RRM2 mRNA was dramatically overexpressed in KB-M2D and KB-HURs compared with parental KB (** p < 0.01). Values of q-RT-PCR were the mean ± SD of three independent experiments and presented as ratio to the level of parental KB cells. (D) q-RT-PCR analysis showed TSP-1 mRNA was significantly decreased in KB-M2D and KB-HURs compared with parental KB (** p < 0.01).

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Overexpression of RRM2 decreased TSP-1 expression in KB-M2-D and KB-HURs cells . (A) Western blot analysis confirmed that only RRM2 was overexpressed in KB-M2-D and KB-HURs; the expression of RRM1 and p53R2 was not significantly modulated in both KB-M2-D and KB-HURs; and the expression of TSP-1 was significantly decreased in KB-M2-D and KB-HURs cells by 60%~70% (TSP1-CM: TSP-1 in concentrated condition medium, TSP1-T: TSP-1 in total protein). (B) Representative quantitative densitometric analysis of RRM2 and TSP-1 expression. Signal intensities were normalized to that of β-actin serving as loading control; data was presented as fold of KB. (C) q-RT-PCR analysis confirmed that RRM2 mRNA was dramatically overexpressed in KB-M2D and KB-HURs compared with parental KB (** p < 0.01). Values of q-RT-PCR were the mean ± SD of three independent experiments and presented as ratio to the level of parental KB cells. (D) q-RT-PCR analysis showed TSP-1 mRNA was significantly decreased in KB-M2D and KB-HURs compared with parental KB (** p < 0.01).

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Over Expression, Expressing, Western Blot, Control, Reverse Transcription Polymerase Chain Reaction

Overexpression of RRM2 increased VEGF expression in KB-M2-D and KB-HURs cells . (A) VEGF in condition mediums of KB-M2-D and Kb-HURs were increased by 2.4-fold and 2.1-fold respectively. Levels of VEGF in the condition medium were measured with ELISA. Data, presented as ng of VEGF protein/ml of medium and per mg of total protein, was the mean ± SD of 2–3 preparation. (B) q-RT-PCR analysis showed that VEGF mRNA was increased in KB-M2D and KB-HURs by 3~4 fold compared with parental KB and KB-V cells. (C) Compared with KB-V, KB-M2-D secreted more VEGF under both normoxia and hypoxia. (D) q-RT-PCR analysis showed KB-M2D expressed more VEGF mRNA than KB-V under both normoxia and hypoxia, * p < 0.05, ** p < 0.01 compared with KB-V.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Overexpression of RRM2 increased VEGF expression in KB-M2-D and KB-HURs cells . (A) VEGF in condition mediums of KB-M2-D and Kb-HURs were increased by 2.4-fold and 2.1-fold respectively. Levels of VEGF in the condition medium were measured with ELISA. Data, presented as ng of VEGF protein/ml of medium and per mg of total protein, was the mean ± SD of 2–3 preparation. (B) q-RT-PCR analysis showed that VEGF mRNA was increased in KB-M2D and KB-HURs by 3~4 fold compared with parental KB and KB-V cells. (C) Compared with KB-V, KB-M2-D secreted more VEGF under both normoxia and hypoxia. (D) q-RT-PCR analysis showed KB-M2D expressed more VEGF mRNA than KB-V under both normoxia and hypoxia, * p < 0.05, ** p < 0.01 compared with KB-V.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Over Expression, Expressing, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction

Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Knockdown, Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Western Blot

Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells . (A) q-RT-PCR analysis confirmed that RRM2 mRNA decreased by ~80%, and TSP-1 mRNA increased by ~8 folds in LNCaP cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~3.4-fold (Ln-Wt: LNCaP cell, Sc-siR: scramble siRNA transfected LNCaP, R2-siR: RRM2 siRNA transfected LNCaP). (C) q-RT-PCR analysis confirmed that RRM2 mRNA was significantly decreased in LNCaP at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in LNCaP cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of LNCaP was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transefected.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells . (A) q-RT-PCR analysis confirmed that RRM2 mRNA decreased by ~80%, and TSP-1 mRNA increased by ~8 folds in LNCaP cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~3.4-fold (Ln-Wt: LNCaP cell, Sc-siR: scramble siRNA transfected LNCaP, R2-siR: RRM2 siRNA transfected LNCaP). (C) q-RT-PCR analysis confirmed that RRM2 mRNA was significantly decreased in LNCaP at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in LNCaP cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of LNCaP was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transefected.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Knockdown, Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Western Blot

Overexpression of RRM2 promoted the growth of KB-M2-D in vivo . (A) Typical RT-CES traces described that KB and KB-M2-D proliferated in an equal rate. CI was recorded every half hour. Each trace for each cell was an average of 4 replicates. (B) Tumor growth curves showed that RRM2 significantly promoted KB-M2-D in vivo growth. (C) Overexpression of RRM2 increased tumor xenografts size of KB-M2-D at the end of experiment. (D) q-RT-PCR analysis confirmed that RRM2, VEGF and TSP-1 mRNA was significantly different in KB-V and KB-M2 xenografts. * p < 0.05; ** p < 0.01, compared with Kb-V. Data expressed was the mean ± SD of 12 mice of two independent experiments.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Overexpression of RRM2 promoted the growth of KB-M2-D in vivo . (A) Typical RT-CES traces described that KB and KB-M2-D proliferated in an equal rate. CI was recorded every half hour. Each trace for each cell was an average of 4 replicates. (B) Tumor growth curves showed that RRM2 significantly promoted KB-M2-D in vivo growth. (C) Overexpression of RRM2 increased tumor xenografts size of KB-M2-D at the end of experiment. (D) q-RT-PCR analysis confirmed that RRM2, VEGF and TSP-1 mRNA was significantly different in KB-V and KB-M2 xenografts. * p < 0.05; ** p < 0.01, compared with Kb-V. Data expressed was the mean ± SD of 12 mice of two independent experiments.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Over Expression, In Vivo, Reverse Transcription Polymerase Chain Reaction

CD31 immunohistochemistry assay displayed that overexpression of RRM2 resulted in more vascularized tumor xenografts . Representative immunohistochemical assay of vascularization of tumor xenografts generated in vivo by (A) KB-V and (B) KB-M2-D cells (×100). (C) Semi-quantitative analysis showed that CD31 staining was significantly increased in KB-M2D tumor xenografts compared with that of KB-V, * p < 0.05. Values expressed were the mean ± SD of 8 mice of two independent experiments.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: CD31 immunohistochemistry assay displayed that overexpression of RRM2 resulted in more vascularized tumor xenografts . Representative immunohistochemical assay of vascularization of tumor xenografts generated in vivo by (A) KB-V and (B) KB-M2-D cells (×100). (C) Semi-quantitative analysis showed that CD31 staining was significantly increased in KB-M2D tumor xenografts compared with that of KB-V, * p < 0.05. Values expressed were the mean ± SD of 8 mice of two independent experiments.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Immunohistochemistry, Over Expression, Immunohistochemical staining, Generated, In Vivo, Staining

Figure 1. In vitro gene silencing efficiency. (A) Relative luciferase activity and cell viability after transfection with EAAS/siRNA and EDAS/siRNA complexes at w/w ratio of 9 and siRNA concentration of 50 nM. (B) Relative RRM2 mRNA level was detected by RT-PCR assay. RRM2 protein level was detected by western blot assay (C) and quantitatively analyzed by Image J software (D). Relative luciferase activity and cell viability were detected after transfected with EAASc/siRNA complexes (E) at different w/w ratios and (F) different siRNA concentrations. To confirm the gene silencing efficiency, relative RRM2 mRNA levels in (G1) HepG2 cells, (G2) MDA-MB-231 cells, (G3) 293A cells, and (G4) Hela cells were also detected at different w/w ratios (5.5, 9, and 14.5) and siRRM2 concentrations (20 nM, 50 nM, and 80 nM). Each bar represents Mean ± SEM of three experiments. * p<0.05, ** p<0.01, and *** p<0.001 vs Naked siRNA group.

Journal: Biomaterials

Article Title: The study of relationships between pKa value and siRNA delivery efficiency based on tri-block copolymers.

doi: 10.1016/j.biomaterials.2018.05.046

Figure Lengend Snippet: Figure 1. In vitro gene silencing efficiency. (A) Relative luciferase activity and cell viability after transfection with EAAS/siRNA and EDAS/siRNA complexes at w/w ratio of 9 and siRNA concentration of 50 nM. (B) Relative RRM2 mRNA level was detected by RT-PCR assay. RRM2 protein level was detected by western blot assay (C) and quantitatively analyzed by Image J software (D). Relative luciferase activity and cell viability were detected after transfected with EAASc/siRNA complexes (E) at different w/w ratios and (F) different siRNA concentrations. To confirm the gene silencing efficiency, relative RRM2 mRNA levels in (G1) HepG2 cells, (G2) MDA-MB-231 cells, (G3) 293A cells, and (G4) Hela cells were also detected at different w/w ratios (5.5, 9, and 14.5) and siRRM2 concentrations (20 nM, 50 nM, and 80 nM). Each bar represents Mean ± SEM of three experiments. * p<0.05, ** p<0.01, and *** p<0.001 vs Naked siRNA group.

Article Snippet: RRM2 antibody was obtained from cell Signaling Technology, Inc. (Danvers, MA) and GAPDH antibody was obtained from Zhongshan Golden Bridge Biotechnology Co., Ltd. (Beijing, China).

Techniques: In Vitro, Luciferase, Activity Assay, Transfection, Concentration Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot, Software

MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as RRM2 ( G , H ) and RRM2B ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Journal: Cancers

Article Title: Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

doi: 10.3390/cancers13164200

Figure Lengend Snippet: MTT viability assay for different dosages of the drug combination cisplatin and gemcitabine after 24 h of incubation for NCI-H295R ( A ) and MUC-1 ( B ) cell lines. Pictures from NCI-H295R ( C ) and MUC-1 ( D ) clonogenic assays for different concentrations of gemcitabine (left) and cisplatin (right) treatment after 24 h incubation. Real-time PCR analysis of RRM1 for NCI-H295R ( E ) and MUC-1 ( F ), as well as RRM2 ( G , H ) and RRM2B ( I , K ). dATP levels for NCI-H295R ( J ) and MUC-1 ( L ) upon different treatments. Quantification of RRM2 protein levels for NCI-H295R ( M ) and MUC-1 ( O ) and RRM2 immunofluorescence (40x) for NCI-H295R ( N ) and MUC-1 ( P ). A representative Western blot used for RRM2 protein expression quantification in NCI-H295R ( Q ) and MUC-1 ( R ) cells. Stars represent significance vs. nontreated for both treatments (*, p < 0.05; **, p < 0.01; ***, p < 0.001).

Article Snippet: The primers used were human RRM2 forward: CTGGCTCAAGAAACGAGGACTG; human RRM2 reverse: CTCTCCTCCGATGGTTTGTGTAC (#HP203086 premixed, Origene, Rockville, MD, USA); human RRM2b forward: ACTTCATCTCTCACATCTTAGCCT; human RRM2b reverse: AAACAGCGAGCCTCTGGAACCT (#HP211794 premixed, Origene); human RRM1 premixed, purchased from Realtimeprimers (#VHPS-8020, Elkins Park, PA, USA).

Techniques: MTT Viability Assay, Incubation, Real-time Polymerase Chain Reaction, Immunofluorescence, Western Blot, Expressing

Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in KB cells . (A) q-RT-PCR analysis showed that RRM2 mRNA was decreased by ~80%, and TSP-1 mRNA was increased by ~5 folds in KB cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~2.6-fold (KB-W: KB cell, Sc-siR: scramble siRNA transfected KB, R2-siR: RRM2 siRNA transfected KB). (C) q-RT-PCR analysis confirmed RRM2 mRNA was significantly decreased in KB cells at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in KB cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of KB was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transfected.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Knockdown, Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Western Blot

Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells . (A) q-RT-PCR analysis confirmed that RRM2 mRNA decreased by ~80%, and TSP-1 mRNA increased by ~8 folds in LNCaP cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~3.4-fold (Ln-Wt: LNCaP cell, Sc-siR: scramble siRNA transfected LNCaP, R2-siR: RRM2 siRNA transfected LNCaP). (C) q-RT-PCR analysis confirmed that RRM2 mRNA was significantly decreased in LNCaP at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in LNCaP cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of LNCaP was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transefected.

Journal: Molecular Cancer

Article Title: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo : implication of RRM2 in angiogenesis

doi: 10.1186/1476-4598-8-11

Figure Lengend Snippet: Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in LNCaP Cells . (A) q-RT-PCR analysis confirmed that RRM2 mRNA decreased by ~80%, and TSP-1 mRNA increased by ~8 folds in LNCaP cells at 48 h post-transfection with RRM2 siRNA. (B) Western blot analysis showed that TSP-1 protein was significantly increased by ~3.4-fold (Ln-Wt: LNCaP cell, Sc-siR: scramble siRNA transfected LNCaP, R2-siR: RRM2 siRNA transfected LNCaP). (C) q-RT-PCR analysis confirmed that RRM2 mRNA was significantly decreased in LNCaP at 48 h post-transfection under both normoxia and hypoxia. (D) q-RT-PCR analysis showed VEGF mRNA in LNCaP cells was decreased after RRM2 knockdown under both normoxia and hypoxia. (E) VEGF in condition medium of LNCaP was significantly decreased after RRM2 knockdown under both normoxia and hypoxia. Data was presented as the mean ± SD of 2–3 independent experiments, * p < 0.05, ** p < 0.01, compared with scramble siRNA transefected.

Article Snippet: The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Techniques: Knockdown, Expressing, Reverse Transcription Polymerase Chain Reaction, Transfection, Western Blot

AFAP1-AS1 upregulates RRM2 expression by sponging miR-139-5p. (A) The potential binding sites between RRM2 and miR-139-5p predicted by bioinformatics. All binding sites in the RRM2 3′ UTR were mutated and named “RRM2 MUT”. (B,C) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (D) RT-PCR on the cDNA from A549 cells to determine the effect of miR-139-5p on RRM2 mRNA expression. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected A549 cells. (E,F) Western blot on the effect of miR-139-5p on protein expression of RRM2, EGFR, AKT, and p-AKT in A549 and SPCA-1 cells. (G) RT-PCR on the expression of RRM2 mRNA in NSCLC tissues ( n = 44) and in adjacent normal tissues ( n = 20). Data shown as means ± S.D. # P < 0.05 compared with the normal tissues. (H) The mRNA level of RRM2 in chemotherapy response ( n = 4) and resistance ( n = 7) NSCLC tumors by RT-PCR. The results shown as means ± S.D. # P < 0.05 compared with the response group. (I) RRM2 mRNA expression in lung cancer cells analyzed by RT- PCR. The results shown as means ± S.D. # P < 0.05 compared with BEAS-2B cells. (J,K) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (L,M) Western blot on the effect of miR-139-5p and AFAP1-AS1 on protein expression of RRM2in A549 and SPCA-1 cells.

Journal: Frontiers in Oncology

Article Title: LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2

doi: 10.3389/fonc.2019.01103

Figure Lengend Snippet: AFAP1-AS1 upregulates RRM2 expression by sponging miR-139-5p. (A) The potential binding sites between RRM2 and miR-139-5p predicted by bioinformatics. All binding sites in the RRM2 3′ UTR were mutated and named “RRM2 MUT”. (B,C) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (D) RT-PCR on the cDNA from A549 cells to determine the effect of miR-139-5p on RRM2 mRNA expression. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected A549 cells. (E,F) Western blot on the effect of miR-139-5p on protein expression of RRM2, EGFR, AKT, and p-AKT in A549 and SPCA-1 cells. (G) RT-PCR on the expression of RRM2 mRNA in NSCLC tissues ( n = 44) and in adjacent normal tissues ( n = 20). Data shown as means ± S.D. # P < 0.05 compared with the normal tissues. (H) The mRNA level of RRM2 in chemotherapy response ( n = 4) and resistance ( n = 7) NSCLC tumors by RT-PCR. The results shown as means ± S.D. # P < 0.05 compared with the response group. (I) RRM2 mRNA expression in lung cancer cells analyzed by RT- PCR. The results shown as means ± S.D. # P < 0.05 compared with BEAS-2B cells. (J,K) A dual luciferase reporter assay on A549 cells and SPCA-1 cells with WT RRM2 3′ UTR or mutated 3′ UTR. Data shown as means ± S.D. # P < 0.05 compared with the pre-NC-transfected or NC-transfected cancer cells. (L,M) Western blot on the effect of miR-139-5p and AFAP1-AS1 on protein expression of RRM2in A549 and SPCA-1 cells.

Article Snippet: We blocked the PVDF membranes in 2% bovine serum albumin (BSA) and incubated them with primary antibodies against RRM2 (catalog No. #65939), EGFR (catalog No. #2085), p-AKT (catalog No. #4060), AKT (catalog No. #9272), and GAPDH (catalog No. #5174) (Cell Signaling Technology, Shanghai, China).

Techniques: Expressing, Binding Assay, Luciferase, Reporter Assay, Transfection, Reverse Transcription Polymerase Chain Reaction, Western Blot

AFAP1-AS1 promotes cell proliferation and chemotherapy resistance through the miR-139-5p/RRM2 axis. A549 or SPCA-1 cells were transfected with scramble, siAFAP1-AS1, siAFAP1-AS1+NC, and siAFAP1-AS1+miR-139-5p inhibitor. (A,B) MTT assay showed miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on lung cancer cell proliferation. (C) and (D) The miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on colony formation. (E,F) The miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on apoptosis of NSCLC cells. (G,H) In A549 and SPCA-1 cells incubated with DDP for 36 h, the miR-139-5p inhibitor reversed the inhibitory effect of siAFAP1-AS1 on chemotherapy resistance (DDP). (I,J) the miR-139-5p inhibitor reversed the inhibitory effect of siAFAP1-AS1 on chemotherapy resistance in cells incubated with 5-FU. (K,L) Knockdown of AFAP1-AS1 downregulated RRM2 protein expression and reduced the protein levels of EGFR and p-AKT, while miR-139-5p reversed these effects in A549, and SPCA-1 cells. All data shown as means ± S.D. # P < 0.05 indicates a significant difference between the two indicated groups.

Journal: Frontiers in Oncology

Article Title: LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2

doi: 10.3389/fonc.2019.01103

Figure Lengend Snippet: AFAP1-AS1 promotes cell proliferation and chemotherapy resistance through the miR-139-5p/RRM2 axis. A549 or SPCA-1 cells were transfected with scramble, siAFAP1-AS1, siAFAP1-AS1+NC, and siAFAP1-AS1+miR-139-5p inhibitor. (A,B) MTT assay showed miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on lung cancer cell proliferation. (C) and (D) The miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on colony formation. (E,F) The miR-139-5p inhibitor reversed the inhibitory effect of AFAP1-AS1 knockdown on apoptosis of NSCLC cells. (G,H) In A549 and SPCA-1 cells incubated with DDP for 36 h, the miR-139-5p inhibitor reversed the inhibitory effect of siAFAP1-AS1 on chemotherapy resistance (DDP). (I,J) the miR-139-5p inhibitor reversed the inhibitory effect of siAFAP1-AS1 on chemotherapy resistance in cells incubated with 5-FU. (K,L) Knockdown of AFAP1-AS1 downregulated RRM2 protein expression and reduced the protein levels of EGFR and p-AKT, while miR-139-5p reversed these effects in A549, and SPCA-1 cells. All data shown as means ± S.D. # P < 0.05 indicates a significant difference between the two indicated groups.

Article Snippet: We blocked the PVDF membranes in 2% bovine serum albumin (BSA) and incubated them with primary antibodies against RRM2 (catalog No. #65939), EGFR (catalog No. #2085), p-AKT (catalog No. #4060), AKT (catalog No. #9272), and GAPDH (catalog No. #5174) (Cell Signaling Technology, Shanghai, China).

Techniques: Transfection, MTT Assay, Knockdown, Incubation, Expressing

RRM2 increases the chemotherapy resistance of NSCLC cells via EGFR/AKT signaling pathway. Cancer cells were transfected with empty vector, RRM2, RRM2+DMSO and RRM2+AST1306, and then incubated with the EGFR inhibitor AST1306 at 1 μM for 24 h. (A,B) In NSCLC cells incubated with DDP for 36 h, overexpression of RRM2 enhanced chemotherapy resistance, and AST1306 reversed this effect. (C,D) In NSCLC cells incubated with 5-FU for 36 h, overexpression of RRM2 enhanced chemotherapy resistance and AST1306 reversed this effect. (E,F) In A549 and SPCA-1 cells, overexpression of RRM2 elevated the protein expression of EGFR and the level of p-AKT, and AST1306 reversed this effect. All data shown as means ± S.D. # P < 0.05 indicates a significant difference between the two indicated groups.

Journal: Frontiers in Oncology

Article Title: LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2

doi: 10.3389/fonc.2019.01103

Figure Lengend Snippet: RRM2 increases the chemotherapy resistance of NSCLC cells via EGFR/AKT signaling pathway. Cancer cells were transfected with empty vector, RRM2, RRM2+DMSO and RRM2+AST1306, and then incubated with the EGFR inhibitor AST1306 at 1 μM for 24 h. (A,B) In NSCLC cells incubated with DDP for 36 h, overexpression of RRM2 enhanced chemotherapy resistance, and AST1306 reversed this effect. (C,D) In NSCLC cells incubated with 5-FU for 36 h, overexpression of RRM2 enhanced chemotherapy resistance and AST1306 reversed this effect. (E,F) In A549 and SPCA-1 cells, overexpression of RRM2 elevated the protein expression of EGFR and the level of p-AKT, and AST1306 reversed this effect. All data shown as means ± S.D. # P < 0.05 indicates a significant difference between the two indicated groups.

Article Snippet: We blocked the PVDF membranes in 2% bovine serum albumin (BSA) and incubated them with primary antibodies against RRM2 (catalog No. #65939), EGFR (catalog No. #2085), p-AKT (catalog No. #4060), AKT (catalog No. #9272), and GAPDH (catalog No. #5174) (Cell Signaling Technology, Shanghai, China).

Techniques: Transfection, Plasmid Preparation, Incubation, Over Expression, Expressing